Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Gene genie: can CRISPR-Cas9 deliver on its promise to transform genome therapy?

Experimental treatments based on CRISPR-Cas9 gene editing technology are at a crossroads, with the first European trial now enrolling patients and new clinical applications and delivery methods steadily emerging. It’s not all good news though; two studies in 2018 found that a majority of patients had T-cell immunity against a type of Cas9. Sally Turner investigates at this important juncture.


Go Top